Nymox Pharmaceutical Corporation – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 40 PAGES: 186

More Info
									Nymox Pharmaceutical Corporation – Product Pipeline
               Review – H2 2011
                                                                                          Reference Code: GMDHC01766CDB

                                                                                                 Publication Date: NOV 2011




Nymox Pharmaceutical Corporation – Product Pipeline Review – H2 2011                        GMDHC01766CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Nymox Pharmaceutical Corporation – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 6
      List of Figures .................................................................................................................................................................................................... 8
Nymox Pharmaceutical Corporation Snapshot.......................................................................................................................................................... 9
      Nymox Pharmaceutical Corporation Overview ................................................................................................................................................... 9
      Key Information .................................................................................................................................................................................................. 9
      Key Facts ........................................................................................................................................................................................................... 9
Nymox Pharmaceutical Corporation – Research and Development Overview .........................................................................................................10
      Key Therapeutic Areas ......................................................................................................................................................................................10
Nymox Pharmaceutical Corporation – Pipeline Review ...........................................................................................................................................12
      Pipeline Products by Stage of Development ......................................................................................................................................................12
      Pipeline Products – Monotherapy .....................................................................................................................................................................13
Nymox Pharmaceutical Corporation – Pipeline Products Glance .............................................................................................................................14
      Nymox Pharmaceutical Corporation – Late Stage Pipeline ................................................................................................................................14
            Phase III Products/Combination Treatment Modalities ................................................................................................................................14
      Nymox Pharmaceutical Corporation–Early Stage Pipeline Products ..................................................................................................................15
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................15
            Discovery Products/Combination Treatment Modalities ..............................................................................................................................16
Nymox Pharmaceutical Corporation – Drug Profiles ................................................................................................................................................17
      NX-1207............................................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
      NXB-4221 .........................................................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      NXB-5886 .........................................................................................................................................................................................................20
            Product Description ....................................................................................................................................................................................20
            Mechanism of Action...................................................................................................................................................................................20
            R&D Progress .............................................................................................................................................................................................20
      NXC-4720 .........................................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      NXD-1191 .........................................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      NXD-3109 .........................................................................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23
            R&D Progress .............................................................................................................................................................................................23
      NXD-5150 .........................................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24
            Mechanism of Action...................................................................................................................................................................................24




Nymox Pharmaceutical Corporation – Product Pipeline Review – H2 2011                                                                                        GMDHC01766CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Nymox Pharmaceutical Corporation – Product Pipeline Review



           R&D Progress .............................................................................................................................................................................................24
     NXD-9062 .........................................................................................................................................................................................................25
           Product Description ....................................................................................................................................................................................25
           Mechanism of Action...................................................................................................................................................................................25
           R&D Progress .............................................................................................................................................................................................25
     NXT-1021 .........................................................................................................................................................................................................26
           Product Description ....................................................................................................................................................................................26
           Mechanism of Action...................................................................................................................................................................................26
           R&D Progress .............................................................................................................................................................................................26
Nymox Pharmaceutical Corporation – Pipeline Analysis ..........................................................................................................................................27
     Nymox Pharmaceutical Corporation – Pipeline Products by Therapeutic Class .................................................................................................27
     Nymox Pharmaceutical Corporation - Pipeline Products By Target ...................................................................................................................28
     Nymox Pharmaceutical Corporation – Pipeline Products by Route of Administration .........................................................................................29
     Nymox Pharmaceutical Corporation – Pipeline Products by Molecule Type ......................................................................................................30
Nymox Pharmaceutical Corporation – Recent Pipeline Updates .............................................................................................................................31
Nymox Pharmaceutical Corporation - Dormant Projects ..........................................................................................................................................33
Nymox Pharmaceutical Corporation – Company Statement ....................................................................................................................................34
Nymox Pharmaceutical Corporation – Locations And Subsidiaries ..........................................................................................................................36
     Head Office .......................................................................................................................................................................................................36
     Other Locations & Subsidiaries .........................................................................................................................................................................36
Recent Developments .............................................................................................................................................................................................37
           Oct 31, 2011: Nymox Presents Long Term Results On NX-1207 BPH Drug At American Urological Association Meeting In New Orleans .37
           Jan 31, 2011: Nymox Provides Update On Phase III Pivotal Trials Of NX-1207 ..........................................................................................37
           Apr 30, 2008: Nymox Announces New Positive Results At 54 Months In Long Term Study Of NX-1207 For Benign Prostatic Hyperplasia 38
           Mar 30, 2010: Nymox's Phase III NX-1207 Drug In Development For Multiple Indications ..........................................................................38
           Jul 28, 2010: Nymox Reports Safety Monitoring Committee Findings For Pivotal Phase III NX-1207 Trials ................................................39
           Oct 27, 2010: Nymox Reports Results From Safety Monitoring Committee Meeting For Pivotal Phase III NX-1207 Trials ..........................40
           Sep 26, 2011: Nymox Announces Publication Of NX-1207 Data In Therapeutic Advances In Chronic Disease For Benign Prostatic
           Hyperplasia.................................................................................................................................................................................................40
           May 25, 2010: Nymox Announces Three Year Follow-Up Results From NX02-0016 US Study Of NX-1207 For BPH .................................41
           Feb 24, 2009: Nymox Announces New Positive Results At 5 Years After Single Treatment In Long Term Study Of NX-1207 For Benign
           Prostatic Hyperplasia ..................................................................................................................................................................................42
           Nov 23, 2009: Nymox Releases Positive New Clinical Trial Data On Durability Of Benefits For Early Responders To Company’s BPH Drug
           NX-1207 .....................................................................................................................................................................................................42
           Jun 22, 2010: Nymox Announces Positive Follow-Up Results From Study NX02-0014 With BPH Drug NX-1207 .......................................43
           Nov 19, 2008: Nymox Announces NEXUS-1 And NEXUS-2 Phase 3 Trials For NX-1207 Investigational Drug For BPH ............................44
           Oct 19, 2011: Nymox Presents New Positive Data On NX-1207 At American Urological Association Meeting ............................................44
           Mar 19, 2007: Nymox Announces Positive Results From Newly Completed Long-Term Study Of NX-1207 For Benign Prostatic Hyperplasia
           ...................................................................................................................................................................................................................45
           Aug 17, 2011: Nymox Provides Update On Phase III Pivotal Trials Of NX-1207 .........................................................................................45
           May 17, 2011: Nymox Pharmaceutical's New Positive Data On NX-1207 Presented At Symposium At American Urological Association
           Annual Meeting ...........................................................................................................................................................................................46
           Aug 16, 2011: Nymox To Present Data On NX-1207 At American Urological Association Meeting .............................................................47
           Mar 16, 2011: Nymox Announces Positive New Results In Seven Year Study Of NX-1207 For Benign Prostatic Hyperplasia ....................47
           Jun 15, 2010: Nymox Reports Near Completion Of New Five Year Long-Term Follow-Up NX02-0014 US Study Of BPH Drug ..................48
           Apr 13, 2011: Nymox Announces New Positive Long-Term 39-45 Month Follow-Up Results From NX02-0016 US Study Of NX-1207 For
           BPH ............................................................................................................................................................................................................48
           Dec 12, 2007: Nymox Reports Update On NX-1207 Study Results, Marketing Plans And Activities............................................................49
           Jun 12, 2002: Nymox Announces Progress With NXD-9062 For Alzheimer Treatment ...............................................................................49
           Oct 11, 2011: Nymox To Present New Clinical Trial Data Of NX-1207 At Orlando Meeting Of American Urological Association .................50




Nymox Pharmaceutical Corporation – Product Pipeline Review – H2 2011                                                                                         GMDHC01766CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                   Page(3)
Nymox Pharmaceutical Corporation – Product Pipeline Review



           May 11, 2010: Nymox Reports Positive Safety Monitoring Committee Update For Pivotal Phase III NX-1207 Trials ...................................51
           May 10, 2011: Nymox To Start Recruitment For NX02-0020 Clinical Trial...................................................................................................51
           Jun 09, 2008: Nymox Starts Phase III Program For NX-1207 .....................................................................................................................52
           Oct 08, 2008: Nymox Updates NX-1207 Product Development Activities ....................................................................................................52
           Oct 07, 2003: Nymox Adds New Drug Candidate, NXD-5150 For Neurodegenerative Disease To Product Pipeline ...................................53
           Jul 07, 2010: Nymox Reports Positive Clinical Trial Data For NX-1207 For Treatment Of Benign Prostatic Hyperplasia .............................53
           May 07, 2007: Nymox Announces New Positive Results From 3 ½ Year Study Of NX-1207 For Benign Prostatic Hyperplasia ..................54
           Aug 06, 1998: Nymox Reports Positive Progress In Spheron Based Drugs For Alzheimer's Disease..........................................................54
           Feb 06, 2008: Nymox Announces Positive Results From New Multi-Center U.S. Study Of NX-1207 For BPH ............................................55
           May 05, 2011: Nymox Announces Presenters And Participants For NX-1207 Symposium To Be Held At American Urological Association
           Annual Meeting ...........................................................................................................................................................................................56
           May 05, 2009: Nymox Announces Start Of Second Phase III Trial For NX-1207 For BPH ..........................................................................56
           Nov 04, 2011: Nymox Announces Presentation On NX-1207 Prostate Drug At American Urological Association Meeting ..........................57
           Oct 04, 2011: Nymox Announces Presentation Of Results On NX-1207 BPH Drug At American Urological Association Meeting ...............57
           May 04, 2011: Nymox Provides Update On Phase III Trials For NX-1207 ............................................................................................
								
To top